UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

New-Onset Diabetes in Covid-19

New England Journal of Medicine, 2020-08, Vol.383 (8), p.789-790

2020

Volltextzugriff (PDF)

Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future

The Lancet (British edition), 2014-03, Vol.383 (9922), p.1068-1083

2014

Volltextzugriff (PDF)

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Diabetes care, 2022-11, Vol.45 (11), p.2753-2786

2022

Volltextzugriff (PDF)

COVID-19, Hyperglycemia, and New-Onset Diabetes

Diabetes care, 2021-12, Vol.44 (12), p.2645-2655

2021

Volltextzugriff (PDF)

Ruolo delle adipochine nella patogenesi del diabete gestazionale

L'Endocrinologo, 2022, Vol.23 (1), p.40-46

2022

Volltextzugriff (PDF)

Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SURPASS-CVOT Design and Baseline Characteristics

The American heart journal, 2024-01, Vol.267, p.1-11

2024

Volltextzugriff (PDF)

Terapia con metformina e rischio di acidosi lattica

L'Endocrinologo, 2018, Vol.19 (Suppl 1), p.1-2

2018

Volltextzugriff (PDF)

Inibitori di SGLT-2 e chetoacidosi euglicemica: conoscere per prevenire

L'Endocrinologo, 2019, Vol.20 (6), p.336-340

2019

Volltextzugriff (PDF)

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

The Lancet (British edition), 2012-04, Vol.379 (9825), p.1498-1507

2012

Volltextzugriff (PDF)

Guida pratica alla prevenzione e gestione dell’infezione da COVID-19 nelle persone con diabete

L'Endocrinologo, 2020, Vol.21 (4), p.241-245

2020

Volltextzugriff (PDF)

I nuovi farmaci per il diabete: gli inibitori del co-trasportatore sodio-glucosio di tipo 2 (SGLT-2i)

L'Endocrinologo, 2016, Vol.17 (5), p.259-261

2016

Volltextzugriff (PDF)

Coxsackie B4 virus infection of β cells and natural killer cell insulitis in recent-onset type 1 diabetic patients

Proceedings of the National Academy of Sciences - PNAS, 2007-03, Vol.104 (12), p.5115-5120

2007

Volltextzugriff (PDF)

Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes

The Journal of clinical investigation, 2007-08, Vol.117 (8), p.2155-2163

2007

Volltextzugriff (PDF)

COVID-19 in people with diabetes: understanding the reasons for worse outcomes

The lancet. Diabetes & endocrinology, 2020-09, Vol.8 (9), p.782-792

2020

Volltextzugriff (PDF)

New forms of insulin and insulin therapies for the treatment of type 2 diabetes

The lancet. Diabetes & endocrinology, 2015-08, Vol.3 (8), p.638-652

2015

Volltextzugriff (PDF)

Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care

The journal of clinical endocrinology and metabolism, 2019-08, Vol.104 (8), p.3296-3302

2019

Volltextzugriff (PDF)

How conclusive is the CONCLUDE trial?

Diabetologia, 2020-04, Vol.63 (4), p.692-697

Del Prato, Stefano

2020

Volltextzugriff (PDF)

Exenatide modulates visual cortex responses

Diabetes/metabolism research and reviews, 2019-09, Vol.35 (6), p.e3167-n/a

2019

Volltextzugriff (PDF)

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes

The New England journal of medicine, 2021-09, Vol.385 (10), p.896-907

2021

Volltextzugriff (PDF)

Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial

The Lancet (British edition), 2019-10, Vol.394 (10208), p.1519-1529

2019

Volltextzugriff (PDF)

Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism?

Diabetes care, 2021-03, Vol.44 (3), p.647-654

2021

Volltextzugriff (PDF)

Diabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters

Diabetes care, 2020-08, Vol.43 (8), p.1695-1703

2020

Volltextzugriff (PDF)

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study

Diabetes care, 2016-05, Vol.39 (5), p.717-725

2016

Volltextzugriff (PDF)

Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin

Diabetes, metabolic syndrome and obesity, 2013-01, Vol.6 (default), p.161-170

2013

Volltextzugriff (PDF)

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study

Diabetes, obesity & metabolism, 2018-11, Vol.20 (11), p.2532-2540

2018

Volltextzugriff (PDF)

1 – 25 von 575

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(510)
Mit Volltextzugriff
(492)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(359)
Life Sciences & Biomedicine
(351)
Humans
(308)
Endocrinology & Metabolism
(238)
Diabetes
(192)
Female
(146)
Male
(136)
Middle Aged
(114)
Diabetes Mellitus
(113)
Adult
(111)
Biological And Medical Sciences
(101)
Medical Sciences
(96)
Diabetes Mellitus, Type 2 - Drug Therapy
(95)
Type 2 Diabetes
(92)
Insulin
(79)
Glucose
(75)
Hypoglycemic Agents - Therapeutic Use
(72)
Cardiovascular System & Cardiology
(69)
Risk Factors
(68)
Aged
(65)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

New-Onset Diabetes in Covid-19

Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

COVID-19, Hyperglycemia, and New-Onset Diabetes

Ruolo delle adipochine nella patogenesi del diabete gestazionale

Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SURPASS-CVOT Design and Baseline Characteristics

Terapia con metformina e rischio di acidosi lattica

Inibitori di SGLT-2 e chetoacidosi euglicemica: conoscere per prevenire

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

Guida pratica alla prevenzione e gestione dell’infezione da COVID-19 nelle persone con diabete

I nuovi farmaci per il diabete: gli inibitori del co-trasportatore sodio-glucosio di tipo 2 (SGLT-2i)

Coxsackie B4 virus infection of β cells and natural killer cell insulitis in recent-onset type 1 diabetic patients

Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes

COVID-19 in people with diabetes: understanding the reasons for worse outcomes

New forms of insulin and insulin therapies for the treatment of type 2 diabetes

Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care

How conclusive is the CONCLUDE trial?

Exenatide modulates visual cortex responses

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes

Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial

Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism?

Diabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study

Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study

Suchergebnisse filtern